Mick J M van Eijs

9PUBLICATIONS
22CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsPredictive and prognostic markersImmunogenetics (incl. genetic immunology)Exercise physiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Nov 18, 2025
Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events.

Mick J M van Eijs, M Marlot van der Wal, Hedi-Britt Klotškova

|Sep 02, 2025
Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment.

S Van Dam, D Krijgsman, E Küçükköse

|Jul 05, 2024
In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients.

Laura M Timmerman, Lobke C M Hensen, Mick J M van Eijs

|Feb 15, 2024
Clinical and translational attributes of immune-related adverse events.

Karijn P M Suijkerbuijk, Mick J M van Eijs, Femke van Wijk

|Nov 24, 2023
Physical activity and checkpoint inhibition: association with toxicity and survival.

Rik J Verheijden, Anna Cabané Ballester, Karel C Smit

|Oct 04, 2023
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.

Mick J M van Eijs, Rik J Verheijden, Stefanie A van der Wees

Pageof 2

Frequent Collaborators

9 joint publications

Karijn P M Suijkerbuijk

7 joint publications

Rik J Verheijden

4 joint publications

Femke van Wijk

3 joint publications

Anne S R van Lindert